TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06585865

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg oral once daily.
Description: Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
Study: NCT06692712

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MELPIDA
Description: Gene Therapy agent
Study: NCT06692114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation, DTMS active
Description: The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Each treatment stimulates at a frequency of 20 Hz for 2 seconds, with a sequence interval of 20 seconds. Each treatment consists of 50 sequences, for a total of 2000 pulses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation, DTMS sham
Description: The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Compared with active treatment, the sham stimulation coil only produced sound and scalp vibration.
Study: NCT06596187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous passive motion device (CPM) of ankle - fast
Description: Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions
Study: NCT06692608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strength training
Description: Comparison between isometric and dynamic strength training in soccer players
Study: NCT05182125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdC6-HIVgp140
Description: The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdC6-HIVgp140
Description: The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdC6-HIVgp140
Description: The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB).
Study: NCT06692608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strength training
Description: Comparison between isometric and dynamic strength training in soccer players
Study: NCT06693453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and Dry cupping
Description: This group will perform electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture and Sham Dry cupping
Description: This group will perform Electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and Sham Dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
Study: NCT06692634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical ventilation setting
Description: VT reduction, EIP setting, RR reduction, and a new EIP programing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical ventilation setting
Description: VT reduction, EIP setting, RR reduction, and a new EIP programing.
Study: NCT06693232

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mobile micro-learning
Description: Mobile micro-learning intervention contains a 10-minute video about cardiopulmonary resuscitation to continuously improve their self-confidence, motivation and reduce their stress
Study: NCT06693388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 2 minutes each exercise with 30 sec break - 4 exercises prior to serial casting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 2 minutes each exercise with 30 sec break - 4 exercises prior to serial casting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Body Vibration
Description: WBV prior to serial casting
Study: NCT05280639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wooden block
Description: Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formal physical therapy or Home Exercise Program
Description: Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
Study: NCT06693388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: Serial Casting as provided by standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: Serial Casting as provided by standard of care
Study: NCT06098274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing program based on transtheoretical model
Description: It will be determined at which stage of change of the transtheoretic model the participants in the intervention group are. A varying number of motivational interviews will be held depending on the stage of change and a maximum of 6 motivational interviews. Those in the preparatory phase will be trained on smartphone addiction. Following completion of the motivational interviewing and training content, the study scales will be re-administered and the effectiveness of the motivational interviewing and training content will be evaluated by comparison with the baseline data.
Study: NCT06693388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: Serial Casting as provided by standard of care
Study: NCT06693206

Intervention type: OTHER
Intervention: Evaluation of aerobic capacity
Description: A stepwise protocol will be used in which the load increases gradually with the bicycle ergometer. In these protocols, the load increases continuously in small amounts throughout the exercise.
Study: NCT06747468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avexitide
Description: Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion
Study: NCT04734704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin swabs at lesional and non-lesional sites
Description: It will be examined in patients skin swabs sampled at lesional and non-lesional sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin swabs at lesional and non-lesional sites
Description: It will be examined in patients skin swabs sampled at lesional and non-lesional sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin swabs at lesional and non-lesional sites
Description: It will be examined in patients skin swabs sampled at lesional and non-lesional sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin swabs on skin
Description: It will be examined in patients skin swabs sampled on skin
Study: NCT04953351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive registration targeted biopsy and TRUS-system biopsy
Description: Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on ultrasound that corresponds to the MRI suspicious regions location. TRUS-system biopsy includes 12 biopsy cores.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI-ultrasound fusion targeted biopsy and TRUS-system biopsy
Description: MRI-ultrasound fusion targeted biopsy is conducted with an mpMRI-TRUS biopsy system that provides realtime fusion of TRUS images and MRI images to guide the biopsy needles. TRUS-system biopsy includes 12 biopsy cores.
Study: NCT04449510

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Cigarette
Description: E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Cigarette
Description: E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Cigarette
Description: E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
Study: NCT06596187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous passive motion device (CPM) of ankle - fast
Description: Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous passive motion device (CPM) of ankle - fast
Description: Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions
Study: NCT06747468

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo comparator
Study: NCT06747091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
Study: NCT05535231

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric test product
Description: 2 capsules of 490 mg Turmeric are taken with water once

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric comparator
Description: 2 capsules of 200 mg Turmeric are taken with water once
Study: NCT06747091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
Study: NCT06748079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3721 inhalation powder
Description: TQC3721 is a target inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TQC3721 inhalation powder
Description: Placebo without drug substance.
Study: NCT06746259

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid point of care test to detect host immune response in ARI
Description: FebriDx is a rapid lateral flow immunoassay for the visual, qualitative, in vitro detection of elevated levels of host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), directly from fingerstick blood to aid in the differentiation of bacterial from non-bacterial acute respiratory infections.
Study: NCT05013034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab Injection
Description: Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
Study: NCT05957978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXE408
Description: Film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium stibogluconate
Description: Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paromomycin
Description: Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.
Study: NCT06747117

Intervention type: DEVICE
Intervention: Indigo Aspiration System
Description: Mechanical aspiration thrombectomy with the Indigo Aspiration System.
Study: NCT05964205

Intervention type: OTHER
Intervention: Electronic clinical decision support tool
Description: Electronic clinical decision support tool
Study: NCT05529927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained-release Dexamphetamine
Description: During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group.
Study: NCT05345873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: one dose of SCTV01E on D0, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: one dose of mRNA-1273 on D0, intramuscular
Study: NCT05694052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted Intervention of environment control
Description: Dynamic light therapy, auditory masking, and rationalization of ICU nocturnal patient activities.
Study: NCT04560543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McCall suture
Description: Laparoscopic suture including the uterosacral ligaments and the peritoneum

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard cuff closure
Description: Standard laparoscopic barbed suture of the vaginal cuff
Study: NCT06081621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGEND001
Description: REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Sodium chloride injection administrated by bronchoscopy.
Study: NCT03816319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine and blood sample collection
Study: NCT05220917

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Any DPP-4 inhibitor claim

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Any DPP-4 inhibitor claim

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Any DPP-4 inhibitor claim

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Any DPP-4 inhibitor claim

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Any DPP-4 inhibitor claim

Intervention type: DRUG
Intervention: GLP-1RA
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: GLP-1RA
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: GLP-1RA
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: GLP-1RA
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: GLP-1RA
Description: Any SGLT2i dispensing claim

Intervention type: DRUG
Intervention: 2nd generation SU
Description: Any 2nd generation SU claim

Intervention type: DRUG
Intervention: 2nd generation SU
Description: Any 2nd generation SU claim

Intervention type: DRUG
Intervention: 2nd generation SU
Description: Any 2nd generation SU claim

Intervention type: DRUG
Intervention: 2nd generation SU
Description: Any 2nd generation SU claim
Study: NCT04724980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGN-2012
Description: In the Phase 1, 3+3 dose escalation clinical trial evaluating PRGN-2012 at two dose levels (1x10\^11 and 5x10\^11 particle units (PU)) administered as adjuvant therapy prior to standard-of-care debulking surgery.~In the Phase 2 segment, PRGN-2012 is evaluated at the RP2D.
Study: NCT04754555

Intervention type: OTHER
Intervention: Arm Activity Measure (ArmA) in french
Description: The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance

Intervention type: OTHER
Intervention: Arm Activity Measure (ArmA) in french
Description: The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance
Study: NCT05166343

Intervention type: DRUG
Group type: OTHER
Intervention: Epinephrine Injection
Description: Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
Study: NCT06079593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gasless Macular hole surgery
Description: Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Macular hole surgery
Description: Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
Study: NCT05407194

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Collagen + vitamin C
Description: Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.
Study: NCT06087458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOY-101
Description: VOY-101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOY-101
Description: VOY-101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOY-101
Description: VOY-101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOY-101
Description: VOY-101